Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13923772 | 0.82 | ADRB1 (0.79) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL4997902 | 0.81 | ADRB1 (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Levobetaxolol SCHEMBL23532 | 0.81 | ADRB1 (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL23530 | 0.81 | ADRB1 (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL23531 | 0.81 | ADRB1 (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL6512495 | 0.81 | ADRB1 (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL42794 | 0.80 | LMNA (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Betaxolol SCHEMBL26664826 | 0.80 | ADRB1 (0.98) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL7930799 | 0.80 | LMNA (0.63) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| Levobetaxolol SCHEMBL42795 | 0.80 | LMNA (1.00) | ADRB1LMNACYP2D6MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| EP-2964224-B1 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT | POLYACTIVA PTY LTD (AU) | 2024-07-03 | — | — | EP | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-11254720-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | ON TARGET THERAPEUTICS LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-20190135882-A1 | Methods and Systems for Designing and/or Characterizing Soluble Lipidated Ligand Agents | ON TARGET THERAPEUTICS LLC | 2019-05-09 | — | — | US | disclosed |
| US-10233219-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | TUFTS MEDICAL CENTER (US) | 2019-03-19 | — | — | US | disclosed |
| US-20160052982-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2016-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | ADRB1 2832/4885LMNA 2571/4885CYP2D6 3622/4885 |
| US-11254720-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | LDLR, HDLBP, LIPG | ADRB1 2832/4885LMNA 2571/4885CYP2D6 3622/4885 |
| US-20190135882-A1 | Methods and Systems for Designing and/or Characterizing Soluble Lipidated Ligand Agents | LDLR, HDLBP, LIPG | ADRB1 2832/4885LMNA 2571/4885CYP2D6 3622/4885 |
| US-20160052982-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | ADRB1 2832/4885LMNA 2571/4885CYP2D6 3622/4885 |
| US-10233219-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | LDLR, HDLBP, LIPG | ADRB1 2832/4885LMNA 2571/4885CYP2D6 3622/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | ADRB1 2832/4885LMNA 2571/4885CYP2D6 3622/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | ADRB1 1777/4885LMNA 3786/4885CYP2D6 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.